JPWO2023089564A5 - - Google Patents
Info
- Publication number
- JPWO2023089564A5 JPWO2023089564A5 JP2024529310A JP2024529310A JPWO2023089564A5 JP WO2023089564 A5 JPWO2023089564 A5 JP WO2023089564A5 JP 2024529310 A JP2024529310 A JP 2024529310A JP 2024529310 A JP2024529310 A JP 2024529310A JP WO2023089564 A5 JPWO2023089564 A5 JP WO2023089564A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- drp
- scd59
- contacting
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163281190P | 2021-11-19 | 2021-11-19 | |
| US63/281,190 | 2021-11-19 | ||
| PCT/IB2022/061158 WO2023089564A1 (en) | 2021-11-19 | 2022-11-18 | Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540470A JP2024540470A (ja) | 2024-10-31 |
| JPWO2023089564A5 true JPWO2023089564A5 (https=) | 2025-11-27 |
| JP2024540470A5 JP2024540470A5 (https=) | 2025-11-27 |
Family
ID=84365536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529310A Pending JP2024540470A (ja) | 2021-11-19 | 2022-11-18 | 可溶性ｃｄ５９を発現する遺伝子療法ベクターにより地図状萎縮を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250018063A1 (https=) |
| EP (1) | EP4433496A1 (https=) |
| JP (1) | JP2024540470A (https=) |
| KR (1) | KR20240107156A (https=) |
| CN (1) | CN118369333A (https=) |
| AU (1) | AU2022394125A1 (https=) |
| CA (1) | CA3237907A1 (https=) |
| IL (1) | IL312903A (https=) |
| JO (1) | JOP20240112A1 (https=) |
| MX (1) | MX2024006087A (https=) |
| WO (1) | WO2023089564A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025074268A1 (en) * | 2023-10-02 | 2025-04-10 | Janssen Biotech, Inc. | Methods for treating macular degeneration |
| WO2025083169A1 (en) * | 2023-10-17 | 2025-04-24 | Tenpoint Therapeutics Limited | Combination of a vegf inhibitor and a complement pathway inhibitor for treating ocular disorders |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4650764A (en) | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
| AU4404785A (en) | 1984-05-25 | 1985-12-31 | Dana-Farber Cancer Institute, Inc. | Ltr vectors, methods of preparation and use |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
| CA1315719C (en) | 1988-02-05 | 1993-04-06 | Arthur Bank | Retroviral packaging cell lines and processes of using same |
| US5112767A (en) | 1988-03-04 | 1992-05-12 | University Of Southern California | Vectors with enhancer domains |
| US6677311B1 (en) | 1988-07-20 | 2004-01-13 | The Salk Institute For Biological Studies | Inducible HSV-TK in transformed cell populations |
| CA1339354C (en) | 1988-09-01 | 1997-08-26 | The Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
| WO1990002797A1 (en) | 1988-09-15 | 1990-03-22 | North Carolina State University | Self-inactivating, replication defective, retroviral vectors and helper cells for producing the same |
| US5124263A (en) | 1989-01-12 | 1992-06-23 | Wisconsin Alumni Research Foundation | Recombination resistant retroviral helper cell and products produced thereby |
| WO1990013641A1 (en) | 1989-05-10 | 1990-11-15 | Sloan-Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
| EP1285967A3 (en) | 1990-09-21 | 2005-03-02 | Chiron Corporation | Human retroviral packaging cell line |
| JP3249516B2 (ja) | 1990-10-31 | 2002-01-21 | ソマティクス セラピー コーポレイション | 遺伝子治療のためのレトロウイルスのベクター |
| US5122767A (en) | 1991-01-10 | 1992-06-16 | Northern Telecom Limited | Saw device tapped delay lines |
| DE69131908T3 (de) | 1991-02-19 | 2008-04-03 | Oxford Biomedica (Uk) Ltd. | Viruspartikel mit veraendertem wirtspektrum |
| AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
| US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5851826A (en) | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| WO2002068627A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| AU2008295509A1 (en) | 2007-08-29 | 2009-03-12 | Tufts University | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| JP5697027B2 (ja) | 2008-02-15 | 2015-04-08 | タフツ ユニバーシティー | マウス網膜上への細胞膜傷害複合体（ｍａｃ）生成のヒト化モデル、並びに、黄斑変性の処置のための組成物とキットと方法 |
| CA2843684A1 (en) | 2010-08-13 | 2012-02-16 | Tufts University | Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein |
| ES2992014T3 (es) * | 2018-02-12 | 2024-12-05 | Tufts College | CD59 para inhibir la activación del inflamasoma |
-
2022
- 2022-11-18 WO PCT/IB2022/061158 patent/WO2023089564A1/en not_active Ceased
- 2022-11-18 US US18/711,131 patent/US20250018063A1/en active Pending
- 2022-11-18 CN CN202280076678.0A patent/CN118369333A/zh active Pending
- 2022-11-18 CA CA3237907A patent/CA3237907A1/en active Pending
- 2022-11-18 JP JP2024529310A patent/JP2024540470A/ja active Pending
- 2022-11-18 MX MX2024006087A patent/MX2024006087A/es unknown
- 2022-11-18 IL IL312903A patent/IL312903A/en unknown
- 2022-11-18 EP EP22814178.4A patent/EP4433496A1/en active Pending
- 2022-11-18 AU AU2022394125A patent/AU2022394125A1/en active Pending
- 2022-11-18 KR KR1020247018900A patent/KR20240107156A/ko active Pending
-
2024
- 2024-05-16 JO JOJO/P/2024/0112A patent/JOP20240112A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7503590B2 (ja) | 遺伝子構築物 | |
| Ong et al. | Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease: Ong et al. | |
| EP2956174B1 (en) | Aav8 retinoschisin expression vector for treating x-linked retinoschisis | |
| JP2022522996A (ja) | オトフェリン遺伝子を回復させるａａｖ媒介遺伝子治療 | |
| CN104994882A (zh) | 使用aavsflt-1治疗amd | |
| IL282053B (en) | Recombinant glut1 adeno-associated viral vector constructs , compositions and kits comprising the same and use thereof | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| US20240218394A1 (en) | Gene therapy for ocular disorders | |
| KR102704296B1 (ko) | Rdh12 암호화 영역을 포함하는 바이러스 벡터 및 망막 이영양증을 치료하는 방법 | |
| EP3823567B1 (en) | Intraocular injection of gene therapy expression vectors | |
| US20200390907A1 (en) | Methods and compositions for treating genetically linked diseases of the eye | |
| Pensado et al. | Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: An approach of gene therapy to treat retinitis pigmentosa | |
| Hojo et al. | Photoreceptor protection by iris pigment epithelial transplantation transduced with AAV-mediated brain-derived neurotrophic factor gene | |
| WO2023169115A1 (zh) | 一种神经系统高亲和性的aav载体及其应用 | |
| US10350306B2 (en) | Methods and compositions for treating genetically linked diseases of the eye | |
| WO2019217582A1 (en) | Aav-compatible laminin-linker polymerization proteins | |
| JPWO2023089564A5 (https=) | ||
| KR20230003569A (ko) | Cdkl5 결핍 장애 (cdd)의 치료에 유용한 조성물 | |
| Singh et al. | Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease–A Focused Review | |
| JP2025508920A (ja) | 新規タンパク質及び核酸配列並びに先天性筋ジストロフィーの予防及び／又は治療におけるそれらの使用 | |
| US20240050520A1 (en) | Gene therapy for treating usher syndrome | |
| CN121754692A (zh) | 一种融合型腺相关病毒药物组合物及应用 | |
| WO2025015328A2 (en) | Increasing nfe2l1 activity or expression as therapy for eye disorders | |
| Fehrman | Feasibility of Large Transgene Delivery to the Mouse Retina: Eyeing the Potential for Gene Therapy Applications | |
| US20240067703A1 (en) | Treatment of glaucoma |